why choose us

First received: February 07, 2023

Clinical Trial: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Small Cell Lung Cancer (SCLC)

Study Type: INTERVENTIONAL


Official Title: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Brief Summary: The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Read more